

LONG TERM RESULTS OF THE ADJUSTABLE CONTINENCE THERAPY (ACT®) FOR RECURRENT FEMALE STRESS URINARY INCONTINENCE

Hypothesis / aims of study

The Adjustable Continence Therapy (ACT®) is a minimally invasive treatment for females with Stress Urinary Incontinence resulting from Intrinsic Sphincter Deficiency (ISD). This study represents the term results of our first series of patients.

Study design, materials and methods

The ACT® devices consist of two silicone balloons sited on either side of the proximal urethra under the bladder neck, each attached to a titanium port buried in the labia allowing post operative titration of the balloons. Female patients who had failed previous pelvic surgery underwent urodynamic assessment; daily pads usage and Incontinence Quality of Life (I-QoL) questionnaire measures prior to implantation of ACT balloons and evaluated post operatively at 1, 3, 6 and 12 months then annually thereafter. Patients were also asked to record their overall impression and percentage of improvement post operatively based on the Patient Global Impression Index (PGI) and Visual Analogue Score (VAS). In addition, complications were recorded.

Results

Sixty females (mean age 67.2 years) have undergone ACT implantation. Mean follow up was 58 months (range 12- 77 months). At last follow-up, mean pad usage improved from 5.9 at baseline to 0.7 and IQOL improved from 29.2 -79.6 with 66% patients completely dry based on VAS. Global assessment indicated 82% were significantly improved, 8% were moderately improved and 10% remained unchanged. Postoperative complications necessitating device removal included migration seen in 8% of patients and urethral erosion in 3.5% of patients. Additionally, 4% balloons were explanted due to device failure. In total, 12 balloons were removed in 11 patients with only 3 patients requiring bilateral removal.

Interpretation of results

Results give us an explicit view of ACT effects in ISD patients. Particularly interesting is the high level of significantly improved patients with the low percentage of post-operative complications.

Concluding message

The relative ease of insertion and the ability to tailor this therapy to individual patient's needs makes this a very attractive option for the challenging treatment of recurrent stress urinary incontinence due to ISD

References

1. Aboseif SR, Franke EI, Nash SD, Slutsky JN, Baum NH, Tu le M, Galloway NT, Pommerville PJ, Sutherland SE, Bresette JF. The adjustable continence therapy system for recurrent female stress urinary incontinence: 1-year results of the North America Clinical Study Group. J Urol. 2009 May;181(5):2187-91. Epub 2009 Mar 17.
2. Kocjancic E, Crivellaro S, Smith JJ 3rd, Ranzoni S, Bonvini D, Frea B Adjustable continence therapy for treatment of recurrent female urinary incontinence. J Endourol. 2008 Jul;22(7):1403-7.
3. Wachter J, Henning A, Roehlich M, Marszalek M, Rauchenwald M, Madersbacher S. Adjustable continence therapy for female urinary incontinence: a minimally invasive option for difficult cases. Urol Int. 2008;81(2):160-6. Epub 2008 Aug 29.

Specify source of funding or grant	Doctor S. Crivellaro, E. Kocjancic and B. Frea are Uromedica's Counselors.
Is this a clinical trial?	No
What were the subjects in the study?	HUMAN
Was this study approved by an ethics committee?	No
This study did not require ethics committee approval because	Because doesn't cause any harm in patients.
Was the Declaration of Helsinki followed?	Yes
Was informed consent obtained from the patients?	Yes